Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Operations (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Cash from Operations data on record, last reported at 28782000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 53.09% year-over-year to 28782000.0; the TTM value through Sep 2025 reached 74824000.0, down 9.02%, while the annual FY2024 figure was 60925000.0, 40.27% up from the prior year.
  • Cash from Operations reached 28782000.0 in Q3 2025 per TNXP's latest filing, down from 14833000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 9919000.0 in Q2 2024 and bottomed at 32911000.0 in Q1 2023.
  • Average Cash from Operations over 3 years is 20283818.18, with a median of 18801000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: soared 57.55% in 2024, then plummeted 53.09% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 22340000.0 in 2023, then skyrocketed by 34.51% to 14630000.0 in 2024, then crashed by 96.73% to 28782000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 28782000.0 in Q3 2025, 14833000.0 in Q2 2025, and 16579000.0 in Q1 2025.